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Abstract
The European Society for Clinical Microbiology and Infectious Diseases established the Sore Throat Guideline Group to write an
updated guideline to diagnose and treat patients with acute sore throat. In diagnosis, Centor clinical scoring system or rapid antigen test
can be helpful in targeting antibiotic use. The Centor scoring system can help to identify those patients who have higher likelihood of
group A streptococcal infection. In patients with high likelihood of streptococcal infections (e.g. 3–4 Centor criteria) physicians can con-
sider the use of rapid antigen test (RAT). If RAT is performed, throat culture is not necessary after a negative RAT for the diagnosis of
group A streptococci. To treat sore throat, either ibuprofen or paracetamol are recommended for relief of acute sore throat symp-
toms. Zinc gluconate is not recommended to be used in sore throat. There is inconsistent evidence of herbal treatments and acupunc-
ture as treatments for sore throat. Antibiotics should not be used in patients with less severe presentation of sore throat, e.g. 0–2
Centor criteria to relieve symptoms. Modest benefits of antibiotics, which have been observed in patients with 3–4 Centor criteria,
have to be weighed against side effects, the effect of antibiotics on microbiota, increased antibacterial resistance, medicalisation and
costs. The prevention of suppurative complications is not a specific indication for antibiotic therapy in sore throat. If antibiotics are indi-
cated, penicillin V, twice or three times daily for 10 days is recommended. At the present, there is no evidence enough that indicates
shorter treatment length.
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Background
Acute sore throat is a symptom often caused by an inflam-
matory process in the pharynx, tonsils or nasopharynx. Most
of these cases are of viral origin and occur as a part of the
common cold. Adults average two to four and children six
to eight upper respiratory tract infections per year usually
during the colder months of the year. In addition to viral
pathogens, bacterial pathogens may also cause pharyngeal
infections. These pathogens include Streptococcus pyogenes
(group A b-haemolytic streptococcus), but groups C or G
b-haemolytic streptococci as well as Mycoplasma pneumoniae
and Chlamydia pneumoniae have also been suggested to be
pathogens. Although rare today in Europe, streptococcal
pharyngitis can be complicated by acute rheumatic fever or
acute glomerulonephritis. Fear of these complications, or a
wish to relieve pain or to satisfy patients often lead physi-
cians to use antibiotic treatment for sore throat.
Acute sore throat is itself a symptom, and pain or
discomfort in the pharynx is not always caused by an
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infectious agent. Conversely, infectious agents are often
found in the pharyngeal area in asymptomatic patients.
There is an apparent lack of studies on sore throat with
simultaneous identification of a wide spectrum of different
infectious agents, both bacterial and viral, alone or mixed,
in symptomatic or asymptomatic children or adults, and
during different seasons.
The European Society for Clinical Microbiology and Infec-
tious Diseases (ESCMID) established the ESCMID Sore
Throat Guideline Group to write an updated guideline to
diagnose and treat patients with acute sore throat. This
guideline answers questions concerning the use of clinical
diagnostic criteria and laboratory diagnostics to detect possi-
ble bacterial infection. In addition to diagnostic recommenda-
tions, the first-choice treatment regimen is also evaluated
and recommendations are given.
The following text is a summary of the recommendations
themselves and a discussion of the evidence on which the
recommendations are based.
Guideline approach
To limit the scope of this guideline we restrict our recom-
mendations to diagnosis and treatment of acute (duration of
symptoms <14 days), uncomplicated sore throat in adults
and children in Europe. The recommendations concern
first-line diagnostics as well as symptomatic and antibiotic
treatment.
The guideline does not cover recurrent or persistent cases
of sore throat, complicated pharyngitis (peritonsillar abscesses,
Lemierre disease, Vincent’s angina), severe comorbidity,
immunosuppression or history of acute rheumatic fever.
Moreover, special circumstances, such as sore throat after tra-
vel outside Europe, sore throat linked to sexual transmission
or rare epidemics (e.g. diphtheria), are not debated.
Methods for literature search
We retrieved the main keywords/MeSH terms from previ-
ous clinical guidelines and reviews on sore throat. We
defined separate search strings according to different
topics, and performed systematic literature searches in
the Medline database, using PubMed, and the Cochrane
Database.
As various guidelines and reviews on sore throat were
published between 2000 and 2002, providing several materi-
als that were considered in this investigation, we decided to
limit our search to the period 2002–2009. More than 1000
articles were reviewed. Abstracts and unpublished studies
were excluded. No studies were excluded a priori for weak-
ness of design or data quality. Detailed search methods are
described in the Appendix.
Grading criteria of evidence
The appraisal of the available evidence was performed fol-
lowing the same lines of reasoning used in the previously
developed guidelines for the management of adult lower
respiratory tract infections [1]. Studies were evaluated
according to their design as well as their potential bias or
validity, to define the strength of evidence they provided. A
checklist for the critical appraisal of each selected publication
was used to assess the validity of selected studies, and their
level of clinical evidence was summarized using criteria
described in Table 1.
A few changes were made to the checklist used by
Woodhead et al. [1], by including specific questions
aimed at the evaluation of potential bias and flaws of
randomized clinical trials, which was particularly useful
for the section on treatment. The evaluated studies
were included in various evidence matrices developed
to answer specific questions on diagnosis, prognosis and
treatment of acute sore throat. Clinical evidence was trans-
lated into recommendations using a protocol described in
Table 2.
TABLE 1. Checklist for levels of evidence in literature
search
Evidence levels
1 Systematic reviews and meta-analyses
2 Randomized trials
3 Prospective cohort
4 Case–control, cross-sectional, retrospective cohort
5 Case reports
6 Expert opinions, consensus statements, other
First suffix
A Low risk of biased results; all or most of the validity criteria are met
(i.e. at least four out of six flaws are unlikely, for randomized trials)
B Moderate risk of biased results; half of the validity criteria are met
(i.e. at least three out of six flaws are unlikely, for randomized trials)
C High risk of biased results; most of the validity criteria are not met
(i.e. two or fewer out of six flaws are unlikely, for randomized trials)
Second suffix
+ Numerical results unequivocally support a positive answer to the research
question (i.e. determinant-outcome relation of interest clearly established)
) Numerical results unequivocally do not support a positive answer to the
research question (i.e. determinant-outcome relation of interest not established)
? Numerical results are unclear
TABLE 2. Checklist for grading recommendations
A Consistent evidence: clear outcome
B Inconsistent evidence: unclear outcome
C Insufficient evidence: consensus
Suffixes
For preventive and therapeutic intervention studies (including harm of
intervention)
1 Systematic reviews (SR) or meta-analyses (MA) of randomized controlled
trials (RCT)
2 One RCT or more than one RCT but no SR or MA
3 One cohort study or more than one cohort study but no SR or MA
4 Other
For other studies
1 Systematic reviews (SR) or meta-analyses (MA) of cohort studies
2 One cohort study or more than one cohort study but no SR or MA
3 Other
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Recommendation summary
Clinical assessment of acute sore throat
What is the role of clinical scoring in the diagnosis of group A
streptococcal infections?
The Centor clinical scoring system can help to
identify those patients who have a higher likelihood
of group A streptococcal infection (A-3). However,
its utility in children appears lower than in adults
because of the different clinical presentation of sore
throat in the first years of life.
Laboratory tests for sore throat
Is throat culture considered a necessary clinical instrument for
diagnosis of group A streptococci?
Throat culture is not necessary for routine diagno-
sis of acute sore throat to detect group A strepto-
cocci (C-3).
What is the validity and accuracy of near patient diagnostic
tests for group A streptococcus? Is it necessary to perform a
throat culture after a negative rapid antigen test (RAT) for the
diagnosis of group A streptococci?
If RAT is performed, throat culture is not neces-
sary after a negative RAT for the diagnosis of
group A streptococci in both children and adults
(B-2).
Is the diagnostic value of RAT increased when tests are per-
formed in subjects with high clinical scores for group A strepto-
cocci, i.e. indicators that increase likelihood of strep throat, as
Centor score or modified Centor score?
In patients with high likelihood of streptococcal
infections (e.g. 3–4 Centor criteria) physicians can
consider the use of RATs. In patients with lower
likelihood of streptococcal infections (e.g. 0–2 Cen-
tor criteria) there is no need to routinely use RATs
(B-3).
Is there a role for additional tests (e.g. C-reactive protein, pro-
calcitonin measurements) in the assessment of severity of acute
sore throat? Does clinical information combined with biomarker
information provide better prognostic information?
It is not necessary to routinely use biomarkers in
the assessment of acute sore throat (C-3).
Does improved diagnosis or the use of near patient tests
improve antibiotic use?
Clinical scoring systems and rapid tests can be
helpful in targeting antibiotic use (B-2).
Treatment
Are analgesics effective in sore throat?
Either ibuprofen or paracetamol are recom-
mended for relief of acute sore throat symptoms
(A-1).
What are the indications for use of glucocorticoids in sore
throat?
Use of corticosteroids in conjunction with antibi-
otic therapy is not routinely recommended for treat-
ment of sore throat. It can however be considered in
adult patients with more severe presentations, e.g.
3–4 Centor criteria (A-1).
What are the indications for use of zinc gluconate in sore throat?
Zinc gluconate is not recommended for use in sore
throat (B-2).
What are the indications for complementary treatments, e.g.
herbal treatments or acupuncture, in sore throat?
There is inconsistent evidence of herbal treat-
ments and acupuncture as treatments for sore
throat (C-1 to C-3).
What is the average benefit from antibiotics and which groups
of patients do benefit from antibiotic treatment?
Sore throat should not be treated with antibiotics
to prevent the development of rheumatic fever and
acute glomerulonephritis in low-risk patients (e.g.
patients with no previous history of rheumatic fever)
(A-1). The prevention of suppurative complications is
not a specific indication for antibiotic therapy in sore
throat (A-1). Clinicians do not need to treat most
cases of acute sore throat to prevent quinsy, acute
otitis media, cervical lymphadenitis, mastoiditis and
acute sinusitis (A-3).
Do antibiotics relieve symptoms in sore throat?
Antibiotics should not be used in patients with less
severe presentation of sore throat, e.g. 0–2 Centor
criteria, to relieve symptoms (A-1). In patients with
more severe presentations, e.g. 3–4 Centor criteria,
physicians should consider discussion of the likely
benefits with patients. Modest benefits of antibiotics,
which have been observed in group A b-haemolytic
streptococcus-positive patients and patients with 3–4
Centor criteria, have to be weighed against side
effects, the effect of antibiotics on the microbiota,
increased antibacterial resistance, medicalization and
costs (A-1).
Which antimicrobial agent is the first choice in patients with
acute sore throat?
If antibiotics are indicated, penicillin V, twice or
three times daily for 10 days, is recommended (A-1).
There is not enough evidence that indicates shorter
treatment length.
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Bacterial pathogens in sore throat
Group A b-haemolytic streptococcus
The role of group A b-haemolytic streptococcus as a bacte-
rial pathogen in sore throat is evident and is not questioned.
Reviews and guidelines considering the diagnosis of sore
throat have therefore been focused mainly or exclusively on
group A streptococci and related symptomatic presentation.
Asymptomatic carriage of b-haemolytic streptococci is fre-
quent, especially in children. According to Tanz and Shulman
[2], over 20% of asymptomatic school children may be carri-
ers of group A streptococcal infection during the winter and
spring. Several European investigations examined the carriage
rates in children and adults. The highest rate was found in
subjects aged 14 years or less (10.9%), whereas rates were
2.3% in patients aged 15–44 years and 0.6% in those aged
45 years or older [3].
Similar results emerged in a Swedish study [4], reporting
carriage rates of 11.3% in 4-year–old children, 5.9% in school
children and 0.8% in adults. In a study from Croatia [5],
carriage rate of group A streptococci was 8.3% overall, with
highest rates being reported for subjects aged 6–14 years.
Higher rates were found in a prospective study conducted in
Turkey on 351 asymptomatic primary school children, as
about 26% of them were group A streptococcal infection
carriers [6].
Complications of group A b-haemolytic streptococcal
pharyngitis are generally rare in both children and adults
(Tables 3 and 4; [7–14]). Potential adverse outcomes include
both suppurative (i.e. quinsy, acute otitis media, cervical
lymphadenitis, mastoiditis, acute sinusitis) and non-suppura-
tive (i.e. acute rheumatic fever, acute glomerulonephritis)
complications. In particular, acute rheumatic fever has been
widely investigated during the last decades, but its incidence
is very low in Europe. Prevention of acute rheumatic fever
depends on effective control of group A streptococcal phar-
yngitis [7] and is important for patients at high risk (e.g.
those who have had rheumatic fever before). Acute glomeru-
lonephritis is another rare consequence of sore throat, fol-
lowing group A streptococcal pharyngitis after a latency
period of a few weeks. Quinsy, a complication that occurs
mainly in young adults, is a polymicrobial infection but group
A streptococcus is the main organism associated with the
disease (Tables 5 and 6; [7–9,11,15–17]).
Tanz and Shulman [2] conclude that pharyngeal carriers of
group A streptococci show an extremely low risk of post-
streptococcal complications, and their likelihood of transmit-
ting the infection is also small.
Group C and G b-haemolytic streptococci
A number of studies are available on the symptomatic pre-
sentation of b-haemolytic streptococci other than group A
streptococci. Two observational studies (one cohort study,
one case–control study) supported a milder clinical presenta-
tion of group C or group G streptococcal pharyngitis than
group A streptococcal pharyngitis (Table 7; [17–25]). On the
other hand, five observational studies (three cohort, two
case–control) and one case series investigation reported a
similar clinical picture.
At least 12 original studies, mostly case series and case
reports, described severe symptoms or complications follow-
ing acute sore throat associated with group C and group G
streptococci (Table 8; [12,25–35]). Cases of severe or recur-
rent pharyngitis because of group C streptococci have been
reported. A case–control study of college students found
that patients with group C streptococci had exudative tonsil-
litis and anterior cervical adenopathy more frequently than
subjects negative for this infection [29]. On the other hand,
there is little evidence to address the issue of whether there
is an association between group G streptococci and severe
or recurrent pharyngitis.
Uncommon complications of pharyngitis caused by group
C or G streptococci that have been reported include reac-
tive arthritis, subdural empyema and acute glomerulonephri-
tis, but a causal relationship was not clearly established. In
1997, Efstratiou reported consistent results of group C and
G septicaemia over a 10-year period [36].
TABLE 3. Summary information on group A streptococci and prognosis of sore throat from papers
First author Type of study Objective Evidence level
Gerber [7] Scientific statement Develop evidence-based recommendations for the prevention
of primary and secondary (recurrent) rheumatic fever
6+
Talmon [8] Case series Describe 11 cases of acute myopericarditis complicating acute tonsillitis 5+
Galioto [9] Review To review diagnosis and treatment of peritonsillar abscess 6+
Abdel-Haq [10] RCS Identify the predisposing factors and the microbiology of RPA 4C?
Martin [11] Review Review of GAS, with focus on its complications 6+
Almroth [12] Case series Study an epidemic of acute glomerulonephritis associated with throat infections 5?
Gerber [13] Review Review on pharyngitis in children 6+
Hanna [14] RCS To describe the epidemiology of peritonsillar abscess disease in Northern Ireland 4B+
GAS, group A streptococci; RCS, retrospective cohort study; RPA, retropharyngeal abscess.
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While sore throat caused by group A streptococci is
known to be rarely associated with acute rheumatic fever in
developed countries, this has not been reported as a compli-
cation following group C or group G streptococcal infection
[37]. There are, however, studies and expert opinions
indicating that group C and group G streptococci might
TABLE 4. Summary information on group A streptococci and prognosis of sore throat from guidelines
Guideline Country Conclusions Age group Evidence level
Agence Franc¸aise de Se´curite´ Sanitaire des
Produits de Sante´ (AFSSAPS)
France There are potentially severe post-streptococcal complications,
i.e. ARF, acute glomerulonephritis and local or systemic septic
complications. However, the risk for ARF is extremely low in
industrialized countries and post-streptococcal acute
glomerulonephritis is rarely the consequence of GAS pharyngitis
Adults 6+
NHS Clinical Knowledge Summaries (CKS) UK Possible complications of streptococcal pharyngitis (rare) were
listed as: otitis media; acute sinusitis; peritonsillar abscess; para/
retropharyngeal abscess; streptococcal pneumonia; mastoiditis;
streptococcal toxic shock syndrome; Lemierre disease; rheumatic
fever; glomerulonephritis
All 6+
National Institute for Health and Clinical
Excellence (NICE)
UK Potential complications of sore throat are ARF, glomerulonephritis,
peritonsillar abscess, acute otitis media, acute rhinosinusitis)
All 6+
Scottish Intercollegiate Guidelines Network (SIGN) UK Incidence of ARF is a potential complication following sore throat,
but it is extremely low in the UK
All 6+
Infectious Diseases Society of America (IDSA) USA The risk of a first attack of ARF is extremely low in adults All 6+
Centers for Disease Control and Prevention (CDC) USA In the vast majority of cases, acute pharyngitis in an otherwise
healthy adult is self-limiting and rarely produces significant sequelae
Adults 6)
ARF, acute rheumatic fever; GAS, group A streptococci.
TABLE 5. Summary information on clinical risk groups in relation to prognosis of sore throat from selected papers
First author Type of study Objective Evidence level
Gerber [7] Scientific statement Develop evidence-based recommendations for the prevention of
primary and secondary (recurrent) rheumatic fever
6+
Talmon [8] Case series Describe 11 cases of acute myopericarditis complicating acute tonsillitis 5+
Galioto [9] Review To review diagnosis and treatment of peritonsillar abscess 6+
Steer [15] Review Review GAS infection in children 6+
Martin [11] Review Review of GAS, with focus on its complications 6+
Hahn [75] Review Review focused on complications of GAS infection 6+
Dunn [17] Case–control To identify which variables predict the development of quinsy 4A+
GAS, group A streptococci.
TABLE 6. Summary information on clinical risk groups in relation to prognosis of sore throat from guidelines
Guideline Country Conclusions Age group Evidence level
NHS Clinical Knowledge Summaries (CKS) UK Subjects at increased risk of complications were defined as those: with
increased risk of severe infections; at risk of immunosuppression; with
history of valvular heart disease; with history of rheumatic fever
All 6+
UK National Institute for Health and
Clinical Excellence (NICE)
UK Specific evidence for complications following sore throat was that male
patients aged 21–40 years who are smokers are significantly more likely to
develop peritonsillar abscess after initial presentation of uncomplicated
sore throat in primary-care settings
All 6+
TABLE 7. Summary information on group C and group G streptococci and symptomatic presentation of sore throat
First author Type of study Objective Evidence level
Fretzayas [18] PCS To identify the clinical features of GCS pharyngitis 3B+
Lindbaek [19] PCS To analyse clinical features of patients with large colony GCS or GGS
compared with patients with GAS and negative cultures
3A)
Zwart [20] Case–control Measure the association between b haemolytic streptococci and sore throat 4A)
Dagnelie [21] PCS To assay the bacterial growth in patients with sore throat 3B)
Turner [22] Case–control Association between GCS and clinical features of pharyngitis 4A)
Gerber [23] PCS Describe an outbreak of GGS pharyngitis 3A)
Meier [24] Case–control To determine whether non-GAS is associated with endemic pharyngitis 4A+
Corson [25] Case report and case series Review of cases of pharyngitis in relation to b-haemolytic streptococci 5)
GAS, group A streptococci; GCS, group C streptococci; GGS, group G streptococci; PCS, prospective cohort study.
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contribute to acute rheumatic fever pathogenesis in high-inci-
dence settings [38,39].
Group C streptococci can cause severe or recurrent
pharyngitis, but there is insufficient evidence for a role of
group C streptococci in other adverse outcomes. There is
insufficient evidence for a role of group G streptococci in
severe/recurrent pharyngitis and other adverse outcomes.
Mycoplasma pneumoniae and Chlamydia pneumoniae
Mycoplasma pneumoniae and C. pneumoniae infection has been
associated with non-streptococcal acute pharyngitis in
selected studies [40]. It is not clear whether pharyngitis due
to these infections may have an unwanted outcome, including
longer duration or recurrence of symptoms and occurrence
of other complications. The available evidence is scanty and
limited to paediatrics (Table 9; [40–44]). Two observational
studies (one prospective cohort, one case–control) reported
increased risk of recurrence of symptoms after M. pneumo-
niae infection. One prospective cohort study reported an
increased risk of recurrence of respiratory illness after
C. pneumoniae infection. Case reports and case series found
a possible association between M. pneumoniae infection and
Bell’s palsy or Stevens–Johnson syndrome.
Clinical assessment of acute sore throat
What is the role of clinical scoring in the diagnosis of group A
streptococcal infections?
The Centor score for the diagnosis of group A strepto-
coccal throat infections was proposed in 1981 [45]. It was
based on the study of 286 adult patients with sore throat
who presented to the Emergency Department at the Univer-
sity College of Virginia. Centor and colleagues identified four
signs and symptoms to estimate the probability of acute
group A streptococcal pharyngitis in adults with sore throat.
The four signs and symptoms were tonsillar exudate,
swollen tender anterior cervical nodes, the lack of cough
and fever. According to the Centor score [45], the risk of
group A streptococcal infection depends on the number of
signs and symptoms, as described in Box 1.
BOX 1.
Number of signs
and symptoms
Risk of group A streptococcal
infection (%)
4 56
3 32
2 15
1 6.5
0 2.5
This clinical decision rule was validated only in adults and
not in children.
The Centor score was later modified by adding age, and was
validated in about 600 adults and children (3–15 years old) in
a Canadian study [46]. The modified Centor score was
based on a total sore throat score that determines the
likelihood of group A streptococcal pharyngitis. To
determine the patient’s total sore throat score it is
necessary to assign points using the criteria detailed in
Box 2.
BOX 2.
Criteria Point
Temperature >38C 1
No cough 1
Tender anterior cervical adenopathy 1
Tonsillar swelling or exudate 1
Age 3–14 years 1
Age 15–44 years 0
Age >44 years )1
The risk of group A streptococcal infection depends on the
total sore throat score (Box 3) [46].
TABLE 8. Summary information on group C and group G stretptococci and prognosis of sore throat
First author Type of study Objective Evidence level
Severe or recurrent pharyngitis
Shah [26] Case report Description of a case of severe GCS pharyngitis 5+
Turner [27] PCS Association between GCS and exudative pharyngitis 3A+
Dudley [28] Case series Report of cases of tonsillitis due to non-GAS 5+
Turner [29] Case–control To determine whether non-GAS is associated with endemic pharyngitis 4A+
Morgan [30] Case report Report of a case of recurrent tonsillopharyngitis due to GCS 5+
Fulginiti [31] Case report Report of a case of recurrent GCS tonsillitis 5+
Reactive arthritis
Jansen [32] Case series To investigate reactive arthritis secondary to throat infection 5+
Young [33] Case report A case of reactive arthritis after GGS pharyngitis 5+
Other adverse outcomes
Almroth [12] Case series Study an epidemic of acute glomerulonephritis associated with throat infections 5?
Natoli [34] Case report Report of a case of streptococcal toxic shock-like syndrome caused by a GCS strain 5+
Gettler [35] Case report GCS subdural empyema after pharyngitis 5+
Corson [25] Case report and case series Review of cases of pharyngitis in relation to b-haemolytic streptococci 5+
GAS, group A streptococci; GCS, group C streptococci; GGS, group G streptococci; PCS, prospective cohort study
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BOX 3.
Total score Risk of group A streptococcal infection (%)
4 38–63
3 27–28
2 10–12
1 4–6
0 2–3
The modified Centor score was further adapted in 2004
[47]. Although the criteria remained the same, the estimated
risk of group A streptococcal infection was updated as
follows (Box 4):
BOX 4.
Total score Risk of group A streptococcal infection (%)
‡4 51–53
3 28–35
2 11–17
1 5–10
£0 1–2.5
Children with acute sore throat have a higher rate of
asymptomatic carriage of group A streptococci than adults
and commonly present with a temperature >38C, tender
anterior cervical adenopathy and tonsillar swelling (e.g.
modified Centor score 3); it is difficult to differentiate
children with streptococcal pharyngitis on the basis of these
scores.
The Centor clinical scoring system can help to identify
those patients who have higher likelihood of group A
streptococcal infection (A-3). However, its utility in children
appears lower than in adults because of the different clinical
presentation of sore throat in the first years of life.
Laboratory tests for sore throat
Is throat culture considered a necessary clinical instrument for
diagnosis of group A streptococci?
The major disadvantage of throat culture in clinical practice
is the delay in obtaining the results (18–24 h or longer).
Further, there is debate as to whether negative cultures
should be re-examined after an additional day to increase
the sensitivity of the test (Tables 10 and 11 [48,49]). Most of
the reviews and guidelines considered do not support throat
culture as a necessary clinical instrument for routine
diagnosis of group A streptococci (Tables 12 and 13; [37,49–
53]).
Throat culture is not necessary for routine diagnosis of
acute sore throat to detect group A streptococci (C-3).
What is the validity and accuracy of near patient diagnostic tests
for group A streptococcus? Is it necessary to perform a throat
culture after a negative RAT for the diagnosis of group A
streptococci?
A wide variety of RATs are available for diagnosing group A
streptococcal pharyngitis, with different diagnostic properties
[37,55].
The great majority of RATs have a high specificity (‡95%)
compared with culturing a throat swab on a sheep blood
agar plate culture [37]. The negative predictive values of the
TABLE 9. Summary information from papers on Mycoplasma pneumoniae and Chlamydia trachomatis infection and prognosis of
sore throat
First author Type of study Objective Evidence level
Esposito [40] PCS To evaluate the natural history of acute tonsillopharyngitis
associated with atypical bacterial infections
3B+
Esposito [41] Case–control To establish the role of atypical bacteria in acute pharyngitis 4A+
Levy [42] Case series + review of case reports Analyse the relation between M. pneumoniae infection and SJS 5+
Klar [43] Case report Case report of an infant who developed bilateral facial paresis 4 weeks
after a febrile illness associated with tonsillitis
5+
Volter [44] Case series Analyse the relation between Bell’s palsy and M. pneumoniae infection 5+
PCS, prospective cohort study; SJS, Stevens–Johnson syndrome.
TABLE 10. Summary information from papers analysing the
optimal duration of incubation of throat cultures
First author
Type of
study Objective Evidence level
Kocoglu [48] PCS Evaluation of accuracy of throat
culture at 24, 48 and 72 h of incubation
3A+
Shulman [49] Review Diagnosis and treatment of acute
streptococcal pharyngitis
6+
PCS, prospective cohort study.
TABLE 11. Summary information from guidelines analysing
the optimal duration of incubation of throat cultures
Guideline Country Conclusions
Age
group
Evidence
level
Infectious Diseases
Society of America
(IDSA)
USA It is advisable to
examine plates that yield negative
results at 24 h again at 48 h
All 6+
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RATs are high, ranging between 93% [52] and 97% [53], and
generally being around 95% [54]. The sensitivity of most
RATs is around 90% (ranging between 86% and 94.8% [37])
compared with culturing a throat swab on sheep blood agar
plate cultures. As reported in several diagnostic accuracy
studies on a specific RAT, the RATs are less sensitive than
declared by the manufacturer [52,55,56]. The positive
predictive values of the RATs ranged between 77% [52] and
97% [57], generally being around 90% [58].
However, the performance of RATs for group A
streptococci is influenced by the skill, experience and
expertise of the individual obtaining the throat swab and
performing the RAT. The performance is also a function of
the clinical characteristics of the illness of the patients
selected for testing. As a result of this bias, often called
‘spectrum bias’, the performance of RAT is not an absolute
feature of a given test [37,59]. To improve the accuracy of
RAT, the RAT should be performed by trained staff [60] and
performed in the posterior pharyngeal wall and both tonsils
(Tables 14 and 15; [49,61,62]).
As already asserted for the first generation of RAT [63], the
new generation of RAT may have an additional value for the
management of sore throat. In children, eight observational
studies (five prospective cohort, three retrospective cohort)
and two guidelines supported the need for confirmation by a
throat culture after a negative RAT. One clinical trial, two
observational studies (both were prospective cohorts) and
one guideline did not consider confirmation by a throat
culture necessary (Tables 16 and 17; [47,50,52,56,57,64–70]).
In adults, except for one prospective study, the
observational study and two guidelines did not support the
need to perform a throat culture after a negative RAT.
If RAT is performed, throat culture is not necessary after a
negative RAT for the diagnosis of group A streptococci in
both children and adults (B-2).
Is the diagnostic value of RAT increased when tests are
performed in subjects with high clinical scores for group A
streptococci, i.e. indicators that increase the likelihood of strep
throat, as Centor score or modified Centor score?
In children and adults, all the observational studies and the
guidelines considered supported higher accuracy of RATs
when these were performed in patients with a high probability
of strep throat (Tables 18 and 19; [54,55,64,66,67,71]). In
conclusion, accuracy of RAT increases in patients with clinical
criteria for group A streptococci, in both children and adults.
TABLE 14. Summary information from papers evaluating
the optimal sites where throat culture should be performed
First author Type of study Objective
Evidence
level
Fox [61] PCS Comparison between testing throat
swab in mouth and throat
3A+
van der Veen [62] PCS Comparison between testing throat
swab on the tonsillar surface and
posterior pharyngeal wall
3A+
Shulman [49] Review Diagnosis and treatment of acute
streptococcal pharyngitis
6+
PCS, prospective cohort study.
TABLE 13. Summary information from guidelines evaluating the use of throat culture in diagnosis of group A streptococcal
sore throat
Guideline Country Conclusions Age group Evidence level
Agence Franc¸aise de Se´curite´ Sanitaire des
Produits de Sante´ (AFSSAPS)
France Use of throat culture is not recommended Adults 6)
NHS Clinical Knowledge Summaries (CKS) UK Throat swabs have poor sensitivity and results
take up to 48 h to be reported
All 6)
Scottish Intercollegiate Guidelines Network (SIGN) UK Throat swabs should not carried out routinely in sore throat All 6)
Centers for Disease Control and Prevention (CDC) USA The use of throat culture for clinical decision making is not
included in the recommendations
Adults 6)
Infectious Diseases Society of America (IDSA) USA Culture of a throat swab remains the standard and if
done correctly, has a high sensitivity
All 6+
The Swedish Strategic Programme for the Rational
Use of Antimicrobial Agents (STRAMA)
Sweden Throat cultures provide support to a suspected clinical
diagnosis of group A streptococci
All 6+
TABLE 12. Summary information from papers evaluating
the use of throat culture in diagnosis of group A
streptococcal sore throat
First author
Type of
study Objective
Evidence
level
Gieseker [50] PCS Accuracy study to evaluate two specific
RATs by comparing with a rigorous throat
culture
3A?
Gerber [37] Review Review of availability data with respect to
the accuracy of RATs and their use
6)
Lindbaek [51] PCS Accuracy study to evaluate a specific RAT
by comparing with two throat cultures
3A?
Matthys [74] Review Comparison of guidelines on pharyngitis 6)
Choby [70] Review Diagnosis and treatment of streptococcal
pharyngitis. Comparison of guidelines
6)
Shulman [49] Review Diagnosis and treatment of acute strepto-
coccal pharyngitis
6+
PCS, prospective cohort study; RAT, rapid antigen test.
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In patients with a high likelihood of streptococcal
infections (e.g. 3–4 Centor criteria) physicians can
consider the use of RATs. In patients with lower
likelihood of streptococcal infections (e.g. 0–2
Centor criteria) there is no need to routinely use RATs
(B-3).
Is there role for additional tests (e.g. C-reactive protein,
procalcitonin measurements) in the assessment of severity of
TABLE 16. Summary information from papers analysing the use of rapid antigen tests in diagnosis of group A streptococcal
sore throat
First author Type of study Objective Evidence level
Gieseker [50] PCS Accuracy study to evaluate two specific RATs by comparing with a rigorous throat culture 3A?
Maltezou [64] RCT Evaluation of a specific RAT in the diagnosis of streptococcal pharyngitis 2B)
Camurdan [57] PCS Evaluation of a specific RAT in the diagnosis of streptococcal pharyngitis 3B)
Humair [54] PCS Evaluation of a specific RAT in the diagnosis of streptococcal pharyngitis 3A)
Forward [52] PCS Evaluation of a specific RAT in the diagnosis of streptococcal pharyngitis 3A+
Van Limbergen [65] PCS Evaluation of a specific RAT in the diagnosis of streptococcal pharyngitis 3B+
Edmonson [66] RCS Evaluation of a specific RAT in the diagnosis of streptococcal pharyngitis 4A+
Hall [67] RCS Evaluation of a specific RAT in the diagnosis of streptococcal pharyngitis 4A+
McIsaac [47] PCS Empirical validation of guidelines for the management of pharyngitis 2A+
Armengol [68] RCS Evaluation of a specific RAT in the diagnosis of streptococcal pharyngitis 4B+
Cohen [69] PCS Evaluation of a specific RAT in the diagnosis of streptococcal pharyngitis 3B)
Gieseker [50] PCS Accuracy study to evaluate two specific RATs by comparing with a rigorous throat culture 3A+
Nerbrand [56] PCS Evaluation of two RATs in the diagnosis of streptococcal pharyngitis 3A+
Choby [70] Review Diagnosis and treatment of streptococcal pharyngitis. Comparison of Guidelines 6?
PCS, prospective cohort study; RAT, rapid antigen test; RCS, retrospective cohort study; RCT, randomized-controlled trial.
TABLE 17. Summary information from guidelines analysing the use of rapid antigen tests in diagnosis of group A
streptococcal sore throat
Guideline Country Conclusions Age group Evidence level
Agence Franc¸aise de Se´curite´ Sanitaire
des Produits de Sante´ (AFSSAPS)
France Negative RAT with low risk for acute rheumatic fever does not
require control culture
All 6)
Infectious Diseases Society of America (IDSA) USA The negative result of a RAT in children should be confirmed using
throat culture unless physicians can guarantee that RAT sensitivity
is similar to that of throat culture in their practice
Children 6?
The Swedish Strategic Programme for the
Rational Use of Antimicrobial Agents (STRAMA)
Sweden If the RAT is negative and suspicions remain that the aetiology is
streptococcal, a throat swab should be taken for culture
All 6+
Finnish Medical Society Duodecim Finland If a RAT is used, a negative result should be verified by culture Children 6+
RAT, rapid antigen test.
TABLE 18. Summary information from papers analysing the combination of use of rapid antigen tests and clinical scores for
diagnosis of group A streptococcal sore throat
First author Type of study Objective Evidence level
Tanz [55] PCS Evaluation of a specific RAT in the diagnosis of streptococcal pharyngitis 3A+
Maltezou [64] RCT Evaluation of a specific RAT in the diagnosis of streptococcal pharyngitis 2B+
Humair [54] PCS Evaluation of a specific RAT in the diagnosis of streptococcal pharyngitis 3A+
Edmonson [66] RCS Evaluation of a specific RAT in the diagnosis of streptococcal pharyngitis 4A+
Hall [67] RCS Evaluation of a specific RAT in the diagnosis of streptococcal pharyngitis 4A+
Atlas [71] PCS Evaluation of a specific RAT in the diagnosis of streptococcal pharyngitis 3B+
PCS, prospective cohort study; RAT, rapid antigen tests; RCS, retrospective cohort study; RCT, randomized-controlled trial.
TABLE 15. Summary information from guidelines evaluating the optimal sites where throat culture should be performed
Guideline Country Conclusions Age group Evidence level
British Columbia Guideline Canada The sterile throat swab should be used by contacting the posterior
pharyngeal wall and the surface of both tonsils
All 6+
Infectious Diseases Society of America (IDSA) USA Throat swab specimens should be obtained from the surface of both
tonsils or tonsillar fossae as well as the posterior pharyngeal wall
All 6+
The Swedish Strategic Programme for the
Rational Use of Antimicrobial Agents (STRAMA)
Sweden The swab is rubbed over both tonsils All 6+
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acute sore throat? Does clinical information combined with
biomarker information provide better prognostic information?
There is no evidence that C-reactive protein levels are
helpful in the diagnosis of acute group A streptococcal sore
throat [72,73]. Anti-DNase B provides useful evidence of
invasive disease but because serial tests are needed, they
cannot be recommended for routine diagnosis in sore throat
[74]. We could find only one review, focused on
complications of group A streptococcal pharyngitis,
concluding that laboratory testing (e.g. erythrocyte
sedimentation rate and C-reactive protein) might be
indicated for suspected post-streptococcal adverse
outcomes [75] (Table 20). Further, we found no evidence
of whether clinical information combined with biomarker
data provides better prognostic information for sore
throat.
It is not necessary, based on current evidence, to routinely
use biomarkers in the assessment of acute sore throat (C-3).
Does improved diagnosis or the use of near patient tests improve
antibiotic use?
One of the major points of disagreement between
international guidelines on the management of acute
pharyngitis is related to indications of the use of rapid tests
[74]. In particular, from the available guidelines, it is still not
clear whether a clinical decision alone, the use of rapid tests,
or a combination of clinical score with rapid tests, should
drive the decision on the use of antibiotics in patients
presenting in the primary-care setting with acute pharyngitis.
Hence, physicians in the USA, France and Finland will
generally adopt a diagnostic test to decide on treatment,
while in the UK and the Netherlands the decision will be
driven by the severity of the disease [74]. In the UK and the
Netherlands no diagnostic tests are used at all.
A number of studies have been published on the issue since
2002. As most investigations provided results stratified
according to age group, we were able to separate the
available data for children (Table 21; [47,49,64]) and adults
(Table 22; [47,54,71,76]). When this was not possible,
studies were considered apart (Table 23; [58,78,79]).
Findings in children and adults were similar. Overall, four
studies indicated that the use of rapid tests (alone) could
reduce antibiotic use, whereas three studies indicated that a
TABLE 21. Papers considering the effect of use of rapid antigen tests/throat swabs/clinical score on antibiotic use in children
First author Type of study Outcome Grade
Maltezou [64] RCT Comparison of three groups: A: private-practice paediatrician, clinical diag-
nosis; B: private-practice paediatrician, diagnosis by RAT and culture; C:
hospital paediatrician, diagnosis by RAT and culture
Use of RAT only: 2B+
Clinical score: 2B)
McIsaac [47] PCS Total and unnecessary antibiotics. Comparison of recommendations of two
guidelines with RAT alone, clinical rules, and treatment for culture positive
St 1: Culture all
St2: IDSA/ASIM1
St3: ASIM2
St4: ASIM3
St5: Modified Centor score and culture approach
St6: RAT approach
Use of RAT only: 2B+
Clinical score: 2B)
Shulman [49] Review Use of RAT and clinical score: 6+
ASIM, American Society of Internal Medicine; IDSA, Infectious Diseases Society of America; PCS, prospective cohort study; RAT, rapid antigen tests; RCT, randomized-
controlled trial.
TABLE 19. Summary information from guidelines analysing the combination of use of rapid antigen tests and clinical scores
for diagnosis of group A streptococcal sore throat
Guideline Country Conclusions Age group Evidence level
Centers for Disease Control and Prevention (CDC) USA Testing only patients with at least two clinical criteria by using a RAT Adults 6+
The Swedish Strategic Programme for the
Rational Use of Antimicrobial Agents (STRAMA)
Sweden Testing only patients with at least two clinical criteria by using a RAT All 6+
RAT, rapid antigen test.
TABLE 20. Summary information from papers on
biomarkers to predict prognosis of sore throat
First author Type of study Objective Evidence level
Hahn [75] Review Review focused on complications
of GAS infection
6+
GAS, group A streptococci.
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strategy involving a combination of clinical score and rapid
test use could reduce antibiotic use.
In conclusion, there is inconsistent evidence on which
diagnostic strategy is best to reduce (unnecessary) antibiotic
use. A strategy based on the use of clinical scores alone may
be associated with higher antibiotic use as compared with
either (i) a combination of clinical score and rapid tests use;
or (ii) use of rapid tests alone.
Clinical scoring systems and rapid tests can be helpful in
targeting antibiotic use (B-2).
Treatment
Are analgesics effective in sore throat?
A systematic review [80] and six randomized-controlled
trials (RCTs) [16,80–85] found that non-steroidal anti-
inflammatory drugs and paracetamol are more effective than
placebo for reducing acute sore throat symptoms in adults.
Ibuprofen and diclofenac are slightly more effective than
paracetamol for pain relief (Table 24; [4,16,80–113]).
Paracetamol and ibuprofen were the safest. In a large RCT,
ibuprofen, when used in accordance with the usual
contraindications, was as well tolerated as paracetamol for
the short-term treatment of the pain of cold and flu
symptoms and of sore throat in adults [94,95]. No trials
were found comparing ibuprofen and diclofenac. A
systematic review showed that ibuprofen and paracetamol
are more effective than placebo for reducing acute sore
throat symptoms in children [80]. Another systematic review
assessed the efficacy and safety of single doses of ibuprofen
and paracetamol for short-term treatment of children’s pain
or fever [96]. The results did not indicate any difference
between the drugs in analgesic efficacy or safety.
TABLE 22. Papers considering the effect of use of rapid antigen tests/throat swabs/clinical score on antibiotic use in adults
First author Type of study Outcome Grade
Worrall [76] RCT, four arms (A: usual practice;
B: decision rules only; C: RAT only;
D: decision rules + RAT)
Prescribing rates and type of AB prescribed Use of RAT only: 2B+
Clinical score: 2B)
Humair [54] PCS Appropriate AB use with five strategies: A: symptomatic treatment; B:
systematic RAT; C: selective RAT; D: empirical AB use; E: systematic
culture
Clinical score: 3A)
Use of RAT and clinical score: 3A+
Atlas [71] 1-year PCS For each patient with symptoms of acute pharyngitis was performed a
RAT and culture. AB prescriptions at the clinical encounter were com-
pared among patients with positive or negative RAT
Use of RAT and clinical score: 3B+
McIsaac [47] PCS Total and unnecessary AB. Comparison of recommendations of two
guidelines with RAT alone, clinical rules, and treatment for culture
positive
St 1: Culture all
St2: IDSA/ASIM1
St3: ASIM2
St4: ASIM3
St5: Modified Centor score and culture approach
St6: RAT approach
Use of RAT only: 2B+
Clinical score: 2B)
Linder [77] RCS A retrospective analysis to determine if clinicians in actual practice use
clinical criteria or microbiological testing to reduce AB prescriptions
Use of RAT and clinical score: 4A+
AB, antibiotic; ASIM, American Society of Internal Medicine; IDSA, Infectious Diseases Society of America; PCS, prospective cohort study; RAT, rapid antigen test; RCS, ret-
rospective cohort study; RCT, randomized-controlled trial.
TABLE 23. Papers considering the effect of use of rapid antigen tests/throat swabs/clinical score on antibiotic use in children
and adults (when it was not possible to separate the results)
First author Type of study Outcome Grade
Johansson [58] PCS 3 months The physicians estimated probability of infection with GAS (6
grading). They also noted management that would have been
used before receiving any test results. The group in which a
majority of the patients were given AB without prior testing
was considered the only clinically positive group in the analysis
Clinical score only: 3A+
McIsaac [78] RCT Control group: a clinical check list
Intervention group: chart stickers that
prompted them to calculate a score based
on clinical findings and provided manage-
ment recommendations linked to score
totals
Unnecessary AB prescriptions given to patients with a negative
throat culture
Prompting clinical score only: 2A)
Rosenberg [79] PCS Use of AB according to results of tests Use of RAT only: 3A+
AB, antibiotic; GAS, group A streptococci; PCS, prospective cohort study; RCT, randomized-controlled trial.
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TABLE 24. Evidence table for studies on treatment of acute sore throat
First author Objective Type of study Evidence level
Timmer [87] To assess the efficacy and safety of Pelargonium sidoides for the treatment of acute respiratory
infections in children and adults
MA 1A+
Shi [88] To assess the efficacy and safety of Chinese herbal medicines for patients with sore throat SR 1A+
Brinckmann [89] To investigate the safety and efficacy of Throat Coat, a traditional demulcent herbal tea, in com-
parison with a placebo tea in the symptomatic treatment of acute pharyngitis
RCT 2A+
Gunsberger [90] To examine the value of acupuncture in the treatment of such common childhood illnesses as
pharyngitis, tonsillitis, and upper respiratory infections
ICS 3C)
Hubbert [91] To compare the efficacy and tolerability of spray (containing a Salvia officinalis fluid extract) against
placebo in the treatment of patients with acute viral pharyngitis
RCT 2B+
Rau [92] To study the effectiveness of the herbal preparation (combination of Capsicum annuum, Guajacum
officinale and Phytolacca americana)
OS 3C+
Wiesenauer [93] To study the efficacy of three plants (combination of Capsicum annuum, Guajacum officinale and Phy-
tolacca americana) used in homeopathy
ICS 3C)
Thomas [80] To estimate the benefits of treatments other than antibiotics for acute sore throat, and the differ-
ences between non-antibiotic interventions and controls in patient-perceived pain of sore throat
SR 1A+
Burnett [82] To determine the time to onset of pain relief from a single dose of a tablet formulation of parac-
etamol containing sodium bicarbonate
RCT 2A+
Gehanno [84] To compare the anti-pyretic and analgesic effects of a single oral dose of diclofenac potassium
6.25, 12.5 or 25 mg with paracetamol 1000 mg and placebo in patients with fever resulting from
acute febrile sore throat
RCT 2A+
Eccles [83] To investigate the efficacy and safety of acetylsalicylic acid (ASA) for the treatment of sore throat
pain associated with upper respiratory infections
RCT 2A+
Schachtel [85] To identify and compare the analgesic activity of a single flurbiprofen lozenge (2.5, 5.0 and
12.5 mg) with placebo in patients with sore throats
RCT 2A+
Watson [16] To study the efficacy of flurbiprofen lozenges compared with placebo RCT 2A+
Benrimoj [81] To determine the single dose efficacy of flurbiprofen 8.75 mg lozenges in comparison with pla-
cebo, over 6 h in patients with sore throat
RCT 2A+
Boureau [86] To validate a slightly modified sore throat pain model by comparing the analgesic efficacy of ibu-
profen with that of paracetamol
RCT 2A+
Moore [94] To identify and quantify factors associated with the occurrence of adverse events in users of anal-
gesic drugs
RCT 2A+
Moore [95] To study the tolerability of ibuprofen, aspirin and paracetamol in patients suffering from cold/flu
or sore throat
RCT 2A+
Perrott [96] To summarize studies testing the efficacy and safety of single-dose acetaminophen and ibuprofen
for treating children’s pain or fever
MA 1A+
Hayward [97] To evaluate whether systemic corticosteroids improve symptoms of sore throat in adults and chil-
dren
MA 1A+
Mossad [98] To test the efficacy of zinc gluconate lozenges in reducing the duration of symptoms caused by
the common cold
RCT 2A+
Macknin [99] To determine the efficacy of zinc gluconate lozenges treatment of colds in children and adoles-
cents
RCT 2A+
Spinks [100] To assess the benefits of antibiotics for sore throat MA 1A+
Cooper [101] To examine the available evidence regarding the diagnosis and treatment of acute GABHS pharyn-
gitis in adult patients
SR 1A+
Spurling [102] To evaluate clinical outcomes, adverse effects, antibiotic use and patient satisfaction associated
with delayed antibiotic prescribing compared with immediate prescribing or no antibiotics for
acute respiratory infections
SR 1A+
Altamimi [103] To summarize the evidence regarding the effect of 2–6 days of oral antibiotics in treating children
with acute streptococcal pharyngitis, compared with a 10-day course of oral penicillin, on duration
of symptoms, eradication of the organism, and recurrence and complication rates
MA 1A+
Casey [104] To compare the relative efficacy of cephalosporins with that of penicillin in the treatment of GAB-
HS tonsillopharyngitis in adults in all available RCTs
MA 1A+
Casey [105] To compare the relative efficacy of cephalosporin and penicillin treatment of GABHS tonsillophar-
yngitis in children in all available RCTs
MA 1A+
Casey [106] To compare the relative efficacy of short-course antibiotic treatment with standard 10-day treat-
ment courses for GAS tonsillopharyngitis
MA 1A+
Ioannidis [107] To compare azithromycin with other antibiotics that typically require longer treatment courses MA 1A+
Esposito [108] To evaluate the efficacy and safety of short-course cefaclor therapy in paediatric GABHS pharyngi-
tis by comparing 5 days of treatment with a cefaclor suspension and 10 days of treatment with an
amoxycillin suspension
RCT 2A+
Sakata [109] To compare a 5-day course of cefcapene-pivoxil with a 10-day course of amoxicillin and a 10-day
course of cefcapene-pivoxil for the treatment of GAS pharyngitis in children
RCT 2B+
Pichichero [110] To compare the amoxicillin sprinkle administered daily for 7 days with penicillin VK four times a
day for 10 days in children with tonsillopharyngitis secondary to Streptococcus pyogenes
RCT 2A+
Gerber [111] To compare the effectiveness of a short (5-day) course of penicillin V potassium with the conven-
tional 10-day oral administration of this antibiotic
RCT 2B+
Schwartz [112] To evaluate the effect of duration of orally administered penicillin V potassium on the bacteriolog-
ical and clinical cure of GAS pharyngitis
RCT 2B+
Stromberg [4] To investigate the possibility of decreasing the length of treatment of GAS pharyngotonsillitis by
comparing the bacteriological and clinical outcomes of a 5-day course of penicillin V with those of
a 10-day course
RCT 2A+
Zwart [113] To assess whether treatment with penicillin for 3 days and the traditional treatment for 7 days
were equally as effective at accelerating resolution of symptoms in patients with sore throat com-
pared with placebo
RCT 2A+
GABHS, group A b-haemolytic streptococcus; GAS, group A streptococcus; ICS, interventional cohort study ; MA, meta-analysis; OS, observational study; RCT, randomized
controlled trial; SR, systematic review.
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Either ibuprofen or paracetamol are recommended for
relief of acute sore throat symptoms (A-1).
What are the indications for use of glucocorticoids in sore
throat?
A systematic review and meta-analysis including eight trials
showed that adults with severe or high Centor scoring sore
throat would benefit from a single dose of corticosteroids in
conjunction with antibiotic therapy [97]. No evidence of
significant benefit was found in children. However, studies
included in the systematic review were not sufficiently
powered to detect adverse effects of short courses of oral
corticosteroids. In addition, steroids might have a
considerably smaller effect in a typical primary-care
population, where most patients do not have severe or high
Centor scoring sore throat [97,114]. The effect of steroids
was also smaller when administered by oral route
(Table 24).
Use of corticosteroids in conjunction with antibiotic therapy
is not routinely recommended for treatment of sore throat.
It can, however, be considered in adult patients with severe
presentations, e.g. 3–4 Centor criteria (A-1).
What are the indications for use of zinc gluconate in the
treatment of sore throat?
The trials on the effectiveness of zinc gluconate provided
conflicting results [98,99]. In both trials patients in the zinc
group had more adverse effects (Table 24). According to the
Cochrane review zinc administered within 24 h of onset of
symptoms reduces the duration and severity of the common
cold in healthy people. However, it is difficult to make firm
recommendations about the dose, formulation and duration
that should be used [115].
Zinc gluconate is not recommended to be used in the
treatment of sore throat (B-2).
What are the indications for complementary treatments, e.g.
herbal treatments or acupuncture in sore throat?
There are no reliable data on the efficacy of alternative
treatment (herbal treatment and acupuncture) on sore
throat [87–93]. In a Cochrane systematic review, the efficacy
of Pelargonium sidoides for the treatment of acute respiratory
tract infections has been studied in two trials on sore throat
[87]. However, both were excluded because of high risk of
bias (Table 24).
Another systematic review on the efficacy of Chinese herbal
medicine for treating sore throat included seven trials [88].
All trials were of methodologically poor quality. In particular,
it was highly likely that there was selection bias or detection
bias, or both, in all of the included trials [88].
One RCT looking at the effectiveness of Throat Coat, a
demulcent herbal tea, in comparison with a placebo tea was
carried out in a small number of patients [89]. Throat Coat
was found to be more effective than placebo for short-term
relief of pain in patients with acute pharyngitis. However,
total pain relief over the first 30 min was not different
between the two groups.
Other studies on the efficacy of herbal treatment and
acupuncture included restricted samples of patients [91] or
were of methodologically poor quality. These three studies
[90,92,93] did not randomize patients between treatment
arms, failing to minimize the effects of selection bias on
study results. In the study by Rau, liquid or tablet
formulation of a herbal compound of Phytolacca, Guajacum
and Capsicum were compared. In the study by Wiesenauer,
combination of three plant substances (Phytolacca americana,
Guajacum officinale, Capsicum annuum) was used in either
solid (tablet) or liquid (drop) formulation. Efficacy is hard to
judge from these studies as they were not placebo-
controlled.
There is inconsistent evidence of herbal treatments and
acupuncture as treatments for sore throat (C-1 to C-3).
What is the average benefit from antibiotics and which groups of
patients benefit from antibiotic treatment?
A Cochrane systematic review and meta-analysis included 27
RCTs assessing the benefits of antibiotics in the management
of sore throat [100]. There was a beneficial effect of
antibiotics in reducing the incidence of rheumatic fever and
acute glomerulonephritis following an episode of sore throat.
However, this effect was present only in trials conducted in
the 1950s and 1960s, during which time the rates of these
complications (especially acute rheumatic fever) were much
higher than now. The absolute risk of developing these
complications following sore throat is extremely small in the
Western world in the first decade of the twenty-first
century and although antibiotic treatment of higher-risk
patients is justified (those with previous rheumatic fever)
antibiotic treatment of lower-risk patients to prevent non-
suppurative complications is not justified [101] (Table 24).
Antibiotics reduced the incidence of acute otitis media and
quinsy (peritonsillar abscess), but did not reduce the
incidence of acute sinusitis in the Cochrane meta-analysis.
However, the relative benefit exaggerates the absolute
benefit because the event rates of suppurative complications
are low. The number needed to treat to benefit was 27 or
higher to prevent one case of quinsy [100,101]. In modern
primary-care settings the number needed to treat to benefit
is between 50 and 200 [113,114].
Sore throat should not be treated with antibiotics to
prevent the development of rheumatic fever and acute
glomerulonephritis in low-risk patients (A-1). The prevention
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of suppurative complications is not a specific indication for
antibiotic therapy in sore throat (A-1). Clinicians do not
need to treat most cases of acute sore throat to prevent
quinsy, acute otitis media, cervical lymphadenitis,
mastoiditis or acute sinusitis (A-3).
Do antibiotics relieve symptoms in sore throat?
Antibiotics have a modest beneficial effect over placebo in
reducing the symptoms of sore throat [100]. In the
Cochrane meta-analysis, antibiotics reduced symptoms of
sore throat on day 3 (pooled Relative Risk 0.72, 95% CI
0.68–0.76) [54]. However, at 1 week, only the group A
b-haemolytic streptococcus-positive subgroup showed a
beneficial effect of antibiotics over placebo (Table 24). In
trials where the Centor criteria were used there was a
modest benefit of antibiotics (1–2 days) [113].
In a systematic review on appropriate antibiotic use for
acute pharyngitis in adults, treatment of antibiotics within 2–
3 days of symptom onset hastened symptomatic
improvement by 1–2 days in patients with group A
b-haemolytic streptococcal pharyngitis [101]. In the
recommendations, the working group combined this
information with our statement that the Centor criteria are
helpful in assessing the presence of a bacterial pharyngitis.
It is not necessary to start antibiotics immediately. A
Cochrane review including ten RCTs compared delayed
antibiotics (more than 48 h after the initial consultation) with
antibiotics used immediately or no antibiotics for acute
respiratory tract infections [102]. No significant differences
were found in complication rates for the three prescribing
strategies. In children, only one RCT of sufficient size and
quality was performed, showing no relevant effects [116].
Antibiotics should not be used in patients with less severe
presentation of sore throat, e.g. 0–2 Centor criteria, to
relieve symptoms (A-1). In patients with more severe
presentations, e.g. 3–4 Centor criteria, physicians should
consider discussion with patients. Modest benefits of
antibiotics (1–2 days), which have been observed in group A
b-haemolytic streptococcus -positive patients and in patients
with 3–4 Centor criteria, have to be weighed against side
effects, the effect of antibiotics on the microbiota, increased
antibacterial resistance, medicalization and costs (A-1). Using
delayed prescribing of antibiotics is a valid option (A-1).
Which antimicrobial agent is the first choice in patients with
acute sore throat?
Penicillin has been the treatment of choice for group A
b-haemolytic streptococcal pharyngitis for five decades and is
recommended by North American and many European
guidelines as first choice for acute sore throat [74]. Penicillin
is chosen because of its proven efficacy, safety, narrow
spectrum and low cost. Amoxicillin is often used in younger
children in place of penicillin V because of taste
considerations and its availability as syrup or suspension in
some countries, but in older children amoxicillin is a poor
first choice because of the risk of severe rash among
patients with Epstein–Barr virus infection. Group A
b-haemolytic streptococci have not developed resistance to
any of the penicillins or shown an increase in penicillin
minimal inhibitory concentrations over at least five decades
[117] (Table 24).
Although newer antibiotics seem to be more effective than
penicillin in reducing sore throat symptoms, the differences
in efficacy are not clinically important. Five systematic
reviews addressed the question of whether penicillin should
remain the treatment of choice. In adults, a meta-analysis of
nine RCTs (2113 patients) comparing cephalosporins with
penicillin (10 days) was performed [104]. The likelihood of
bacteriological and clinical failure in the treatment of group
A b-haemolytic streptococcal tonsillopharyngitis was two
times higher for oral penicillin than for oral cephalosporins;
the OR for clinical cure rate was 2.29 (95% CI 1.61–3.28)
favouring cephalosporin treatment. In children, 35 trials
including 7125 patients were included in a meta-analysis
[105]. The OR for clinical cure rate was 2.34 (95% CI 1.84–
2.97) favouring cephalosporins. Although clinical cure rates
favoured cephalosporins, the magnitude of the differences in
both meta-analyses was small and not clinically relevant.
Major flaws of these reviews were discussed by Shulman and
Gerber [118] and Bisno [119]. Another meta-analysis by the
same authors [118,119] compared bacterial and clinical cure
rates in children and adults with group A streptococcal
tonsillopharyngitis treated with oral b-lactam or macrolide
(other than azithromycin) antibiotics [106]. Twenty-two
trials with 7470 patients were included in four separate
analyses. Four or 5 days of cephalosporin therapy was
superior to 10 days of penicillin therapy in terms of bacterial
cure rate: OR 1.47 (95% CI 1.06–2.03). The overall clinical
cure rate, however, was 1.35 (95% CI 0.90–2.03) and it was
even lower in the studies of good quality.
A systematic review comparing efficacy and safety of
azithromycin against other antibiotics for acute pharyngitis in
adults and children found no evidence of differing efficacy
between azithromycin and comparator agents [107].
Comparator drugs were penicillin (n = 7), clarithromycin
(n = 3), cefaclor (n = 3), erythromycin (n = 1),
roxythromycin (n = 1) and co-amoxiclav (n = 1), all typically
prescribed for 10 days.
Apart from the aforementioned reviews, two RCTs
compared efficacy of cephalosporins and amoxicillin in
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children [108,109]. No significant differences in clinical
cure rate were found in both trials. Another RCT
compared the efficacy of amoxicillin and penicillin in
children with acute streptococcal tonsillopharyngitis [110].
The clinical cure rates for amoxicillin and penicillin were
86% and 92%, respectively, confirming that amoxicillin
could be an alternative regimen for the treatment of
streptococcal tonsillopharyngitis in children. Penicillin and
amoxicillin are also supported by their sufficient
antibacterial spectrum and lower cost.
Traditionally, a regimen of penicillin for 10 days was
recommended for the treatment of sore throat to maximize
eradication of bacteria. In western countries in 2011,
penicillin is prescribed primarily to shorten the course of the
sore throat and not to prevent complications.
If shorter duration therapy is as effective as 10-day
treatment, shortening the duration could improve
compliance and reduce adverse effects. The aforementioned
review by Casey and Pichichero [104] also reviewed trials
comparing 5-day courses of penicillin with 10-day courses of
penicillin and saw small clinical differences in outcome
favouring 10 days of treatment. Another RCT assessed the
clinical and bacteriological effects of a 3-day and a 7-day
regimen of penicillin V in adult patients with sore throat,
selected by clinical criteria [113]. Penicillin treatment for
7 days was superior to treatment for 3 days or placebo in
resolving the symptoms of sore throat.
A Cochrane review and meta-analysis [103] summarized the
evidence regarding the efficacy of short-duration newer
antibiotics (2–6 days) compared with 10 days of oral
penicillin in treating children with acute group A b-
haemolytic streptococcal pharyngitis. Twenty studies were
included with 13 102 cases of acute group A b-haemolytic
streptococcal pharyngitis. The short-duration treatment
showed slightly better clinical outcome: shorter periods of
fever [mean difference )0.30 days, 95% CI )0.45 to )0.14]
and throat soreness (mean difference )0.50 days, 95% CI
)0.78 to )0.22); lower risk of early clinical treatment failure
(OR 0.80, 95% CI 0.67–0.94), no significant difference in
early bacteriological treatment failure (OR 1.08, 95% CI
0.97–1.20) or late clinical recurrence (OR 0.95, 95% CI
0.83–1.08). More side effects were seen in the short-
duration treatment group (OR 1.85, 95% CI 1.55–2.21).
Most of the events involved the gastrointestinal system
(diarrhoea, vomiting and abdominal pain) in both treatment
groups. The two lengths of treatment were difficult to
compare because different types of antibiotics were compared
in most trials and differences found in clinical outcomes were
small.
If antibiotics are indicated, penicillin V, twice or three
times daily for 10 days, is recommended (A-1). There is
not enough evidence that indicates shorter treatment
length.
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Appendix: Search methods
Diagnosis
We searched the scientific literature, with restrictions
according to year of publication and language, as follows:
(sore throat OR pharyngitis OR tonsillitis OR pharyngo-
tonsillitis OR tonsillopharyngitis) AND (rapid antigen OR
rapid test OR rapid tests OR swab OR swabs OR throat cul-
ture) AND (streptococcus OR streptococcal OR strep)
AND ((English[lang])) AND ((‘2002’[PDat]: ‘2010’[PDat])).
On 15 April 2009, we retrieved 182 papers (including 14
reviews) using PubMed. Potentially relevant articles were
assessed by one reviewer, who excluded those that were
not in the scope for this topic of the guideline (e.g. studies
on antibiotic use, investigations focused on prognosis or on
diseases other than those of the upper respiratory tract,
studies that were clearly not conducted in the primary-care
setting, those from developing countries, etc.) on the basis
of title, abstract (when available), and keywords (MeSH
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terms). From the first selection, 113 papers were eliminated.
Sixty-nine papers were selected for further consideration.
Two other papers of interest were found in the Cochrane
Database, and two were found by looking at the reference
list of the selected papers, for a total of 73 articles (see
Appendix for the full list). All of these papers were carefully
considered for the development of guideline indications,
though not all provided relevant information.
Prognosis—streptococci
We searched the scientific literature, with restrictions
according to year of publication and language, as follows:
((prognosis OR complication * OR outcome * OR rheu-
matic fever) AND (sore throat OR pharyngitis OR tonsillitis
OR pharyngotonsillitis OR tonsillopharyngitis) AND (strepto-
coccus OR streptococcal OR strep) AND ((English[lang]))
AND ((‘2002’[PDat]: ‘2010’[PDat]))).
On 15 September 2009, we retrieved 372 papers (includ-
ing 71 reviews). Potentially relevant articles were assessed
by one reviewer, who excluded those that were not in the
scope for this topic of the guideline (e.g. those not focused
on upper respiratory tract infections, studies on treatment
or diagnosis, investigations from developing countries, studies
on socio-economic costs, etc.) on the basis of title, abstract
(when available), and keywords (MeSH terms). From the first
selection, 327 papers were eliminated. Forty-five papers
were selected for further consideration. Two further articles
were retrieved by looking at reference lists of the papers
selected for consideration (see Appendix for the full list). All
these papers were carefully considered for the development
of guideline indications, though not all provided relevant
information.
Prognosis—Mycoplasma pneumoniae or Chlamydia
pneumoniae
We searched the scientific literature with a specific string
for M. pneumoniae or C. pneumoniae infections, with restric-
tion according to language but not year of publication, as fol-
lows:
((prognosis OR complication * OR outcome * OR rheu-
matic fever) AND (sore throat OR pharyngitis OR tonsillitis
OR pharyngotonsillitis OR tonsillopharyngitis) AND (M. pneu-
moniae OR C. pneumoniae) AND ((English[lang]))).
On 15 September 2009, we retrieved 33 papers (including
eight reviews). Potentially relevant articles were assessed by
one reviewer, who excluded those that were not in the
scope for this topic of the guideline (e.g. those focused on
other agents involved in upper respiratory tract infections,
studies on treatment or diagnostic tests, studies on socio-
economic costs, reports of outbreaks, etc.) on the basis of
title, abstract (when available), and keywords (MeSH terms).
From the first selection, 24 papers were eliminated. Nine
papers were selected for further consideration (see Appen-
dix for the full list). All these papers were carefully consid-
ered for the development of guideline indications, though
not all provided relevant information.
Infection with group C or group G streptococci
We searched the scientific literature, with restrictions
according to language and year of publication (limited to
studies published from 1980 onwards), as follows:
(sore throat OR pharyngitis OR tonsillitis OR pharyngo-
tonsillitis OR tonsillopharyngitis) AND (((C) OR (G)) AND
group) AND (streptococcus OR streptococcal OR strep)
AND ((English[lang])).
On 15 September 2009, we retrieved 295 papers (includ-
ing 27 reviews). Potentially relevant articles were assessed
by one reviewer, who excluded those that were not in the
scope for this topic of the guideline (mostly, those investigat-
ing group A streptococci, studies not focused on upper
respiratory tract infections, studies on treatment, molecular
and mechanistic studies) on the basis of title, abstract (when
available), and keywords (MeSH terms). From the first selec-
tion, 233 papers were eliminated, and 62 papers were
selected for further consideration (see Appendix for the full
list). All these papers were carefully considered for the
development of guideline indications, though not all provided
relevant information.
Treatment
We searched the scientific literature for studies conducted
in the primary-care setting, with restrictions according to
language (English), and excluding studies conducted in devel-
oping countries, using the following search strategy (com-
bined MeSH and text word search) and abstract appraisal
criteria:
#1 sore throat
#2 pharyngitis
#3 tonsillitis
#4 pharyngotonsillitis
#5 tonsillopharyngitis
#6 nasopharyngitis
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6
#8 complementary treatment OR complementary thera-
pies OR complementary medicine
#9 alternative treatment OR alternative treatments OR
alternative medicine OR traditional medicine
#10 phytotherapy OR herbal OR herb OR herbs
#11 medicinal plant OR medicinal plants
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#12 Echinacea OR chamomile OR eucalyptus OR garlic OR
sage OR raspberry OR licorice root
#13 marshmallow root OR Althae´a officina´lis OR pelargo-
nium OR calendula
#21 #8 OR #9 OR #10 OR #11 OR #12 OR #13
#22 #7 AND #21 (307 hits)
# 22 is the final search strategy for the part on com-
plementary treatment.
#23 symptomatic treatment OR symptomatic treatments
#24 analgesic OR analgesics
#25 acetaminophen OR paracetamol
#26 Anti-inflammatory agents, Non-steroidal OR non-
steroidal anti-inflammatory OR nonsteroidal anti-inflamma-
tory OR NSAID OR NSAIDs
#27 aspirin OR acetylsalicylic acid
#28 ibuprofen
#29 #23 OR #24 OR #25 OR #26 OR #27 OR #28
#30 #7 AND #29 (480 hits)
#30 is the final search strategy for the part on
symptomatic treatment.
#31 Anti-bacterial agents OR antimicrobial OR antimicro-
bials OR anti-microbial OR anti-microbials OR antibiotic OR
antibiotics OR anti-bacterial OR antibacterial OR antibacte-
rials
#32 penicillin
#33 erythromycin
#34 amoxicillin
#35 cephalosporin OR cephalosporins OR azithromycin OR
clarithromycin OR quinolone OR tetracycline OR doxy-
cycline OR co-trimoxazole
#36 #31 OR #32 OR #33 OR #34 OR #35
#37 #7 AND #36 (3097 hits)
#37 is the final search strategy for the part on anti-
biotic treatment (questions 3–6).
#38 mouthwashes OR mouthwash OR throat spray OR
lozenge Or lozenges OR gargle OR gargles OR mouth rinse
OR mouth rinses
#39 #7 AND #38 (86 hits)
#39 is additional search strategy
Abstract appraisal criteria:
 title or abstract addresses one or more of the study
questions;
 title or abstract identifies primary research or systemati-
cally conducted secondary research
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